Great Valley Advisor Group Inc. Has $16.29 Million Stock Holdings in AbbVie Inc. $ABBV

Great Valley Advisor Group Inc. cut its stake in AbbVie Inc. (NYSE:ABBV) by 4.6% in the 4th quarter, Holdings Channel.com reports. The fund owned 71,310 shares of the company’s stock after selling 3,462 shares during the quarter. Great Valley Advisor Group Inc.’s holdings in AbbVie were worth $16,293,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Cowa LLC raised its holdings in AbbVie by 19.8% in the 4th quarter. Cowa LLC now owns 6,165 shares of the company’s stock valued at $1,409,000 after acquiring an additional 1,018 shares in the last quarter. Absolute Capital Management LLC increased its stake in shares of AbbVie by 18.5% in the 4th quarter. Absolute Capital Management LLC now owns 1,158 shares of the company’s stock valued at $265,000 after purchasing an additional 181 shares during the last quarter. Nuveen LLC increased its stake in shares of AbbVie by 6.5% in the 4th quarter. Nuveen LLC now owns 8,608,026 shares of the company’s stock valued at $1,966,848,000 after purchasing an additional 524,495 shares during the last quarter. Xponance LLC increased its stake in shares of AbbVie by 3.4% in the 4th quarter. Xponance LLC now owns 479,552 shares of the company’s stock valued at $109,573,000 after purchasing an additional 15,898 shares during the last quarter. Finally, Advisory Resource Group increased its stake in shares of AbbVie by 7.5% in the 4th quarter. Advisory Resource Group now owns 2,091 shares of the company’s stock valued at $478,000 after purchasing an additional 146 shares during the last quarter. 70.23% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on ABBV shares. Royal Bank Of Canada started coverage on AbbVie in a research report on Tuesday, February 24th. They set an “outperform” rating and a $260.00 price objective on the stock. Evercore set a $235.00 price objective on AbbVie in a research report on Friday, May 15th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $240.00 target price on shares of AbbVie in a report on Thursday, April 30th. Guggenheim reaffirmed a “buy” rating and set a $249.00 target price on shares of AbbVie in a report on Friday, May 1st. Finally, Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, June 7th. Three analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, AbbVie presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Analysts and media coverage highlighted AbbVie’s Skyrizi and Rinvoq as key growth drivers, noting strong first-quarter performance and the potential for continued sales momentum through 2026, including additional indications. Will Skyrizi & Rinvoq Continue to Drive AbbVie’s Topline Through 2026?
• Positive Sentiment: Another market commentary framed AbbVie as a growth-pharma stock at a value-pharma price, reinforcing the view that its earnings growth and pipeline may justify the valuation. AbbVie: Growth-Pharma Profile At A Value-Pharma Price
• Positive Sentiment: AbbVie was also featured on CNBC’s “Final Trades”, which can support investor sentiment by keeping the stock in the market spotlight. AbbVie, Devon Energy and more on CNBC’s ‘Final Trades’
• Neutral Sentiment: Several pieces described AbbVie as a stock worth watching or holding after a strong run, with valuation and balance-sheet concerns tempering enthusiasm but not signaling a major change in the business outlook. Up 45% Since 2024: 1 Glaring Reality That Makes AbbVie Stock a Hold at $225
• Negative Sentiment: AbbVie also faced a FDA Complete Response Letter for its fast-acting neurotoxin TrenibotE, citing manufacturing-related issues. While the letter reportedly raised no safety or efficacy concerns, it delays the program and adds near-term regulatory uncertainty. FDA Issues Complete Response Letter for AbbVie’s Fast-Acting Neurotoxin TrenibotE; Spokane dermatologist Dr. Philip Werschler on What the Letter Means

AbbVie Stock Performance

ABBV stock opened at $225.04 on Friday. The stock’s 50 day simple moving average is $210.80 and its 200 day simple moving average is $219.01. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The company has a market cap of $397.60 billion, a P/E ratio of 110.86, a price-to-earnings-growth ratio of 0.69 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The business had revenue of $15 billion for the quarter, compared to the consensus estimate of $14.72 billion. During the same period in the prior year, the business earned $2.46 EPS. The firm’s revenue for the quarter was up 12.4% on a year-over-year basis. Equities analysts predict that AbbVie Inc. will post 14.3 earnings per share for the current year.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.